We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.48%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$30.4M
Cap. Flow
-$14.2M
Cap. Flow %
-5.45%
Top 10 Hldgs %
85.17%
Holding
28
New
8
Increased
4
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$6.74M
3
DERM
Dermira, Inc.
DERM
+$5.69M
4
LOXO
Loxo Oncology, Inc
LOXO
+$4.12M
5
NTRA icon
Natera
NTRA
+$2.72M

Top Sells

Rank Stock Value
1
AKAO
Achaogen Inc
AKAO
+$28M
2
NTLA icon
Intellia Therapeutics
NTLA
+$7.43M
3
EDIT icon
Editas Medicine
EDIT
+$4.46M
4
IRTC icon
iRhythm Holdings
IRTC
+$3.31M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 49.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTX
26
Akari Therapeutics
AKTX
$14M
– –
-246
Closed -$1.39M
EDIT icon
27
Editas Medicine
EDIT
$413M
– –
-274,910
Closed -$4.46M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-63,627
Closed -$919K
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q1 2017 Portfolio in Review

As of Q1 2017, Foresite Capital Management III held 28 positions worth $261M, up 13% from $230M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Foresite Capital Management III withdrew a net $14.2M in Q1 2017, closing 3 positions and reducing 9 holdings. Its most notable exit was Editas Medicine, an estimated $4.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 51% a quarter earlier.

Against the trend, Foresite Capital Management III opened a new position in Bellicum Pharmaceuticals, Inc. worth $11.3M.

  • Foresite Capital Management III's largest Q1 2017 buy was Bellicum Pharmaceuticals, Inc.: 91,800 shares worth $11.3M.
  • Foresite Capital Management III added most to Epizyme, Inc in Q1 2017, an estimated $1.02M increase.
  • Foresite Capital Management III's biggest Q1 2017 reduction was Achaogen Inc, cutting an estimated $28M.
  • Foresite Capital Management III fully exited Editas Medicine in Q1 2017, selling an estimated $4.46M.
  • Foresite Capital Management III's ten largest holdings make up 85% of its $261M portfolio in Q1 2017.
  • Foresite Capital Management III opened 8 new positions and closed 3 in Q1 2017.
  • Foresite Capital Management III's portfolio value rose 13% quarter-over-quarter to $261M.

Based on Foresite Capital Management III's 13F filing for Q1 2017, filed 12 May 2017.